Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 5:2020:2078279.
doi: 10.1155/2020/2078279. eCollection 2020.

Upregulated Expression of Intestinal Antimicrobial Peptide HD5 Associated with Renal Function in IgA Nephropathy

Shaozhen Feng  1   2 , Zhong Zhong  1   2 , Jinjin Fan  1   2 , Xiaoyan Li  1   2 , Dianchun Shi  1   2 , Lanping Jiang  1   2
Affiliations

Upregulated Expression of Intestinal Antimicrobial Peptide HD5 Associated with Renal Function in IgA Nephropathy

Shaozhen Feng et al. Dis Markers. .

Erratum in

Abstract

Purpose: It was reported that gut-kidney axis may play an important role in IgA nephropathy (IgAN). Previous five GWASs of different populations for IgAN have discovered several genes related to intestinal immunity, including DEFA gene. However, the roles of the encoded proteins of DEFA5/6 which were called intestinal antimicrobial peptides HD5 and HD6 were not clear in kidney disease, such as IgAN. The purpose of this study was to clarify the association of HD5 and HD6 with IgAN.

Methods: We measured HD5 and HD6 in serum, urine, and kidney of IgAN patients and normal controls by ELISA, Western blot, and immunofluorescence. The association of HD5 or HD6 levels with clinical and pathologic phenotypes was analyzed.

Results: Serum levels of HD5 and HD6 were significantly higher in IgAN patients than those in normal controls. Baseline serum HD5 levels were significantly associated with eGFR (P = 0.002) and tubular atrophy/interstitial fibrosis (P = 0.002) and tubular atrophy/interstitial fibrosis (P = 0.002) and tubular atrophy/interstitial fibrosis (P = 0.002) and tubular atrophy/interstitial fibrosis (.

Conclusions: In IgAN patients, an elevated serum HD5 level at the time of renal biopsy was associated with poor renal outcomes. HD5 rather than HD6 was probably associated with renal function of IgAN patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Scatter dot plots of HD5 and HD6 measurements in IgAN patients. ELISA was used to determine the serum levels of HD5 (a) and HD6 (b), as well as urinary levels of HD5 (c) and HD6 (d) in Chinese IgAN patients and normal controls. Line indicates median with interquartile range. P value analysis: nonparametric test (Mann-Whitney U).
Figure 2
Figure 2
Scatter dot plot and gender difference of serum HD6 in IgAN patients. ELISA was used to determine the serum levels of HD6 in Chinese IgAN patients as Figure 1. Line indicates median with interquartile range. P value analysis: nonparametric test (Mann-Whitney U).
Figure 3
Figure 3
Kaplan-Meier analysis of cumulative renal survival of patients with IgAN based on the serum HD5 level at renal biopsy. Survival curves significantly differ (log-rank test, chi − square test = 0.870, P = 0.009).
Figure 4
Figure 4
Expression levels of HD5 in the kidney of IgAN. Human kidney labeled for HD5 (red), proximal tubule marker AQP-1 (green), and nuclei (blue). HD5 (red) showed production in the damaged proximal tubules with the exception of normal proximal tubules (arrow). Scale bar = 50 μm.
Figure 5
Figure 5
Western blot analysis of serum HD5 in normal controls (N) and IgAN patients (I).
See this image and copyright information in PMC

References

    1. D’Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. QJM: An International Journal of Medicine. 1987;64(3):709–727. doi: 10.1093/oxfordjournals.qjmed.a068143. - DOI - PubMed
    1. Tsukamoto Y., Wang H., Becker G., et al. Report of the Asian Forum of Chronic Kidney Disease Initiative (AFCKDI) 2007. “Current status and perspective of CKD in Asia”: diversity and specificity among Asian countries. Clinical and Experimental Nephrology. 2009;13(3):249–256. doi: 10.1007/s10157-009-0156-8. - DOI - PubMed
    1. Hiki Y., Odani H., Takahashi M., et al. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy. Kidney International. 2001;59(3):1077–1085. doi: 10.1046/j.1523-1755.2001.0590031077.x. - DOI - PubMed
    1. Barratt J., Feehally J. IgA nephropathy. Journal of the American Society of Nephrology. 2005;16(7):2088–2097. doi: 10.1681/ASN.2005020134. - DOI - PubMed
    1. Donadio J. V., Grande J. P. IgA nephropathy. The New England Journal of Medicine. 2002;347(10):738–748. doi: 10.1056/NEJMra020109. - DOI - PubMed

LinkOut - more resources